Orexigen Therapeutics, Inc   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: La Jolla CA United States (2002)
Status: Defunct (2014)

Organization Overview

First Clinical Trial
2005
NCT00364871
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Orexigen Therapeutics, Inc

Active Ingredients

Drugs in Phase 4 Trials (2)

bupropion (wellbutrin) (17 trials)

naltrexone (revia) (16 trials)

Drugs in Phase 2 Trials (3)

fluoxetine (prozac) (1 trial)

olanzapine (zyprexa) (1 trial)

zonisamide (Zonegran) (3 trials)

Drugs in Phase 1 Trials (2)

moxifloxacin (avelox) (1 trial)

sitagliptin (januvia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Body Weight (Phase 3)

Cardiovascular Diseases (Phase 4)

Compulsive Personality Disorder (Phase 2)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Disease (Phase 2)

Obesity (Phase 4)

Obsessive-Compulsive Disorder (Phase 2)

Overweight (Phase 3)

Psychotic Disorders (Phase 2)

Schizophrenia (Phase 2)

Tobacco Use Disorder (Phase 2)

Weight Gain (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 7